First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    InspireMD Inc.

    NSPR · 3 developments mapped · last assessed 2026-09-21

    Market Ontology has mapped 3 macro, policy, and market developments to InspireMD Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for NSPR yet, so no modelled value is shown. The NSPR valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run NSPR on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for NSPR. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      InspireMD, Inc. Initiates $9 Million Annualized Cost Savings Program

      Direct cost reduction leading to improved profitability and cash flow.

      · Moves future profitability growth, free cash flow generation

    • Open question

      InspireMD Announces Amendments to Series J and Series K Warrants for Potential $11 Million Proceeds

      Direct capital raise, potential dilution, and financing certainty tied to product approval.

      · Moves future cash flows (due to increased capital), dilution impact on per share metrics, probability of successful product launch

    What changed, by assumption

    Future cash flows (due to increased capital)
    • 2026-09-21InspireMD Announces Amendments to Series J and Series K Warrants for Potential $11 Million Proceeds
    Probability of successful fda approval and subsequent commercialization
    • 2026-09-21InspireMD Announces Amendments to Series J and Series K Warrants
    Future profitability growth
    • 2026-08-17InspireMD, Inc. Initiates $9 Million Annualized Cost Savings Program

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-21Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-09-21Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-07-02Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-07-02Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-07-02RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-21InspireMD Announces Amendments to Series J and Series K Warrants for Potential $11 Million Proceedsmixed1-3m0.70
    2026-09-21InspireMD Announces Amendments to Series J and Series K Warrantsmixed3-12m0.70
    2026-08-17InspireMD, Inc. Initiates $9 Million Annualized Cost Savings ProgramBullish3-12m0.70